CN104508120A - 编码肝素结合血凝素(hbha)融合蛋白质的重组分枝杆菌和其用途 - Google Patents

编码肝素结合血凝素(hbha)融合蛋白质的重组分枝杆菌和其用途 Download PDF

Info

Publication number
CN104508120A
CN104508120A CN201280073116.7A CN201280073116A CN104508120A CN 104508120 A CN104508120 A CN 104508120A CN 201280073116 A CN201280073116 A CN 201280073116A CN 104508120 A CN104508120 A CN 104508120A
Authority
CN
China
Prior art keywords
mycobacterium
protein
hbha
methods
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280073116.7A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·富尔克森
迈克尔·布伦南
卡马拉坎南·韦尔穆鲁甘
卡米耶·洛赫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French National Institute Of Health And Medicine
Aeras Global TB Vaccine Foundation
Original Assignee
French National Institute Of Health And Medicine
Aeras Global TB Vaccine Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by French National Institute Of Health And Medicine, Aeras Global TB Vaccine Foundation filed Critical French National Institute Of Health And Medicine
Publication of CN104508120A publication Critical patent/CN104508120A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
CN201280073116.7A 2012-04-16 2012-04-16 编码肝素结合血凝素(hbha)融合蛋白质的重组分枝杆菌和其用途 Pending CN104508120A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/033757 WO2013158061A1 (en) 2012-04-16 2012-04-16 Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
CN104508120A true CN104508120A (zh) 2015-04-08

Family

ID=49383839

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280073116.7A Pending CN104508120A (zh) 2012-04-16 2012-04-16 编码肝素结合血凝素(hbha)融合蛋白质的重组分枝杆菌和其用途

Country Status (6)

Country Link
US (2) US9926346B2 (https=)
EP (1) EP2838990A4 (https=)
JP (1) JP2015515276A (https=)
CN (1) CN104508120A (https=)
IN (1) IN2014DN08675A (https=)
WO (1) WO2013158061A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112746051A (zh) * 2020-12-24 2021-05-04 中国人民解放军空军特色医学中心 一种表达甲基化hbha蛋白的重组耻垢分枝杆菌菌株、制备方法及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591375B2 (en) * 2018-01-22 2023-02-28 Oregon State University Immunogenic compositions comprising Mycobacterium bovis surface proteins and uses thereof
CA3097569A1 (en) * 2018-04-17 2019-10-24 The Johns Hopkins University Recombinant therapeutic interventions for cancer
US12359209B2 (en) 2018-04-17 2025-07-15 The Johns Hopkins Unversity Recombinant therapeutic interventions for cancer
WO2024187255A1 (en) 2023-03-14 2024-09-19 Instituto Butantan Process of submerged cultivation of slow-growing mycobacterium bovis, bacillus calmette-guérin or recombinant forms thereof in a bioreactor and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1966689A (zh) * 2005-11-15 2007-05-23 华中科技大学 一种卡介苗表达载体及其构建
US20090123438A1 (en) * 2004-11-16 2009-05-14 Menzo Jans Emco Havenga Multivalent Vaccines Comprising Recombinant Viral Vectors
CN101816783A (zh) * 2010-04-15 2010-09-01 中国人民解放军第四军医大学 一种表达hbha-il-12融合蛋白的重组耻垢分枝杆菌疫苗
WO2011013097A2 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
WO2011144951A1 (en) * 2010-05-21 2011-11-24 Health Protection Agency Mycobacterial antigen composition
EP2437061A1 (en) * 2010-09-30 2012-04-04 Ikonomopoulos, John Mycobacterial protein detection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US6949345B1 (en) 1996-05-17 2005-09-27 Institut National De La Sante Et De La Recherche Medicale Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin
CA2285625C (en) 1997-04-02 2015-06-30 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis
CA2451045A1 (en) * 2001-06-21 2003-09-04 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
FR2832410B1 (fr) * 2001-11-19 2004-04-02 Pasteur Institut Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
US7829104B2 (en) 2004-12-01 2010-11-09 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
WO2006060332A2 (en) 2004-12-01 2006-06-08 Aeras Global Tb Vaccine Foundation Electroporation of mycobacterium and overexpression of antigens in mycobacteria
CN101198358B (zh) 2004-12-01 2013-06-26 Aeras全球Tb疫苗基金会 具有增强的逃出内体能力的重组bcg菌株
GB0500102D0 (en) 2005-01-05 2005-02-09 Isis Innovation Method for generating a memory t cell response

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123438A1 (en) * 2004-11-16 2009-05-14 Menzo Jans Emco Havenga Multivalent Vaccines Comprising Recombinant Viral Vectors
CN1966689A (zh) * 2005-11-15 2007-05-23 华中科技大学 一种卡介苗表达载体及其构建
WO2011013097A2 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
CN101816783A (zh) * 2010-04-15 2010-09-01 中国人民解放军第四军医大学 一种表达hbha-il-12融合蛋白的重组耻垢分枝杆菌疫苗
WO2011144951A1 (en) * 2010-05-21 2011-11-24 Health Protection Agency Mycobacterial antigen composition
EP2437061A1 (en) * 2010-09-30 2012-04-04 Ikonomopoulos, John Mycobacterial protein detection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIRREN, B.等: "Accession Number: EAY58892.1", 《GENBANK》 *
RONGGAI SUN等: "Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis", 《VACCINE》 *
XIU-YUN HE等: "Assessment of Five Antigens from Mycobacterium tuberculosis for Serodiagnosis of Tuberculosis", 《 ASSESSMENT OF FIVE ANTIGENS FROM MYCOBACTERIUM TUBERCULOSIS FOR SERODIAGNOSIS OF TUBERCULOSIS》 *
周珊 等: "肝素结合血凝素蛋白在结核病诊断中的应用研究", 《检验医学》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112746051A (zh) * 2020-12-24 2021-05-04 中国人民解放军空军特色医学中心 一种表达甲基化hbha蛋白的重组耻垢分枝杆菌菌株、制备方法及其应用

Also Published As

Publication number Publication date
WO2013158061A1 (en) 2013-10-24
US20180305416A1 (en) 2018-10-25
US20150291669A1 (en) 2015-10-15
EP2838990A4 (en) 2016-08-10
JP2015515276A (ja) 2015-05-28
IN2014DN08675A (https=) 2015-05-22
EP2838990A1 (en) 2015-02-25
US9926346B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
KR102515835B1 (ko) UspA2 단백질 구축물 및 그의 용도
CN106103471B (zh) 异源寡聚分枝杆菌抗原的融合
CA2759583C (en) A tuberculosis tb vaccine to prevent reactivation
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
JP6470179B2 (ja) 結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
KR102393038B1 (ko) OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도
US20180305416A1 (en) Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof
WO2017205225A2 (en) Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
CN102276730A (zh) 金黄色葡萄球菌IsdBid-TRAP融合蛋白制备方法及其应用
Cho et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus
CN104560780B (zh) 产气荚膜梭菌ε毒素减毒突变体及其应用
CN107349423B (zh) 一种脑膜炎球菌抗原组合及其应用
CN106536544B (zh) 艰难梭菌免疫原性组合物
CN101124335B (zh) 高通量蛋白组学
KR102130925B1 (ko) 면역원성시스템 및 이를 포함한 동물 백신
JP2018134074A (ja) ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム
BE1022553A1 (fr) Mutants de spy0269
US20230045642A1 (en) S. aureus antigens and compositions thereof
EP3230444A1 (en) Neisseria meningitidis trypsin-like serine protease polypeptides and compositions thereof
KR101713635B1 (ko) 비브리오 패혈증균의 시스테인 단백질 분해효소 도메인 유래 재조합 단백질 및 이의 용도
BE1022553B1 (fr) Mutants de spy0269
HK1124071A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150408

RJ01 Rejection of invention patent application after publication